By Barbara S. Wiggins
Taken directly from the ACC
The use of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AF) weighing ≥120 kg was not associated with an increased risk of thromboembolic events or bleeding compared to those patients weighing 60-120 kg.
The results of this study add to the growing body of literature demonstrating that DOACs are a reasonable alternative for patients with non-valvular AF who are obese, specifically those with a body weight exceeding 120 kg.
Reference
Wiethorn, E.E., Bell, C.M. & Wiggins, B.S. Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥ 120 Kilograms versus 60–120 Kilograms. Am J Cardiovasc Drugs 21, 545–551 (2021). https://doi.org/10.1007/s40256-021-00470-0
